A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
← catalyst calendarNCT06703606 · readout in 259 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
15estimated
Sites
7
Countries
India, Turkey (Türkiye), United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-13 | actual | When the study began enrolling |
| Primary completion | 2027-05-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-05 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Severe Hemophilia A
Intervention
- Drug: MARSTACIMAB — also filed as PF-06741086
Primary outcomes
what the primary-completion date above is the date OFIncidence of marstacimab-related adverse events (AEs)
measured Approximately 178 days: from the time the participant provides informed consent, through and including a minimum of 28 calendar days after last dose of study treatment
Incidence of marstacimab-related serious AEs (SAEs)
measured Approximately 178 days: from the time the participant provides informed consent, through and including a minimum of 28 calendar days after last dose of study treatment
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed